Denali Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.59M Buy
375,965
+109,500
+41% +$2.21M 0.76% 37
2026
Q1
$5.22M Buy
266,465
+54,700
+26% +$1.34M 0.58% 61
2025
Q4
$5.67M Buy
211,765
+76,765
+57% +$1.98M 0.63% 53
2025
Q3
$3.6M Buy
+135,000
New +$3.49M 0.41% 84
2022
Q1
Sell
-5,700
Closed -$133K 378
2021
Q4
$133K Buy
+5,700
New +$117K 0.05% 175

Other funds holding AMPH

Denali Advisors's AMPH Position: Q2 2026 in Review

Denali Advisors increased its Amphastar Pharmaceuticals (AMPH) stake by 41% in Q2 2026, buying an estimated $2.21M and bringing the position to 375,965 shares worth $7.59M. The position accounts for 0.76% of the portfolio, ranked #37.

Denali Advisors first reported a position in AMPH in Q4 2021 and has held it in 5 quarters since. 212 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Denali Advisors held 375,965 shares of Amphastar Pharmaceuticals worth $7.59M as of Q2 2026.
  • Denali Advisors bought 109,500 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $2.21M.
  • Amphastar Pharmaceuticals made up 0.76% of Denali Advisors's portfolio in Q2 2026, its #37 holding.
  • Denali Advisors first reported a position in Amphastar Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
  • 212 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Denali Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.